NO865179L - Fremgangsmaate for fremstilling av optisk aktive 2-klor-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo(d,g)(1,3,6)dioxazociner. - Google Patents
Fremgangsmaate for fremstilling av optisk aktive 2-klor-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo(d,g)(1,3,6)dioxazociner.Info
- Publication number
- NO865179L NO865179L NO865179A NO865179A NO865179L NO 865179 L NO865179 L NO 865179L NO 865179 A NO865179 A NO 865179A NO 865179 A NO865179 A NO 865179A NO 865179 L NO865179 L NO 865179L
- Authority
- NO
- Norway
- Prior art keywords
- dibenzo
- chloro
- methylpropyl
- dimethylamino
- dioxazocine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 18
- -1 3-DIMETHYLAMINO-2-METHYLPROPYL Chemical class 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- SQODSURYUNVIBL-UHFFFAOYSA-N 3-(3-chlorobenzo[d][1,3,6]benzodioxazocin-5-yl)-n,n,2-trimethylpropan-1-amine Chemical compound O1COC2=CC=C(Cl)C=C2N(CC(CN(C)C)C)C2=CC=CC=C21 SQODSURYUNVIBL-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- 150000007524 organic acids Chemical class 0.000 claims description 13
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 239000012452 mother liquor Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- JCVUTMRTBZIRFR-LREBCSMRSA-N 3-(3-chlorobenzo[d][1,3,6]benzodioxazocin-5-yl)-n,n,2-trimethylpropan-1-amine;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1COC2=CC=C(Cl)C=C2N(CC(CN(C)C)C)C2=CC=CC=C21 JCVUTMRTBZIRFR-LREBCSMRSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000001358 L(+)-tartaric acid Substances 0.000 description 5
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 5
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- JSUAJTLKVREZHV-UHFFFAOYSA-N 1-[4-(1-pyrrolidinyl)but-2-ynyl]pyrrolidine Chemical compound C1CCCN1CC#CCN1CCCC1 JSUAJTLKVREZHV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- MNPXCHCSWCJIDS-UHFFFAOYSA-N dioxazocine Chemical compound C1=CC=NOOC=C1 MNPXCHCSWCJIDS-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- FZCRQGMMAHHLMV-UHFFFAOYSA-N 3-(3-chlorobenzo[d][1,3,6]benzodioxazocin-5-yl)-n,n,2-trimethylpropan-1-amine;hydrochloride Chemical compound Cl.O1COC2=CC=C(Cl)C=C2N(CC(CN(C)C)C)C2=CC=CC=C21 FZCRQGMMAHHLMV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000648 anti-parkinson Effects 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KKOZKXBAPIYWAT-JTQLQIEISA-N (2s)-2-[(4-methylphenyl)sulfonylamino]pentanedioic acid Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 KKOZKXBAPIYWAT-JTQLQIEISA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- NWCHELUCVWSRRS-UHFFFAOYSA-N atrolactic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GWZCCUDJHOGOSO-UHFFFAOYSA-N diphenic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1C(O)=O GWZCCUDJHOGOSO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000003165 hydrotropic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
- Y02T50/00—Aeronautics or air transport
- Y02T50/10—Drag reduction
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Luminescent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU854881A HU195491B (en) | 1985-12-20 | 1985-12-20 | Process for production of optically active 2-chlor-12-/3-/dimethil-amin/-2-methil-prophil/-12h-dibenzol /d,g/ /1,3,6/-diaxazocine and medical compositions containing such compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO865179D0 NO865179D0 (no) | 1986-12-19 |
| NO865179L true NO865179L (no) | 1987-06-22 |
Family
ID=10969129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO865179A NO865179L (no) | 1985-12-20 | 1986-12-19 | Fremgangsmaate for fremstilling av optisk aktive 2-klor-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo(d,g)(1,3,6)dioxazociner. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4906622A (de) |
| JP (1) | JPS62158265A (de) |
| CN (1) | CN86108260A (de) |
| AT (1) | AT394366B (de) |
| AU (1) | AU589725B2 (de) |
| BE (1) | BE905907A (de) |
| BG (1) | BG46004A3 (de) |
| CA (1) | CA1291133C (de) |
| CH (1) | CH670638A5 (de) |
| CS (1) | CS262681B2 (de) |
| DD (1) | DD256695A5 (de) |
| DE (1) | DE3643991A1 (de) |
| DK (1) | DK616886A (de) |
| ES (1) | ES2003994A6 (de) |
| FI (1) | FI83644C (de) |
| FR (1) | FR2592043B1 (de) |
| GB (1) | GB2184445B (de) |
| HU (1) | HU195491B (de) |
| IT (1) | IT1199821B (de) |
| NL (1) | NL8603236A (de) |
| NO (1) | NO865179L (de) |
| PH (1) | PH24385A (de) |
| PL (1) | PL263134A1 (de) |
| PT (1) | PT83979B (de) |
| SE (1) | SE466399B (de) |
| SU (1) | SU1470187A3 (de) |
| YU (1) | YU45814B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU198194B (en) * | 1986-12-30 | 1989-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for production of new derivatives of dioxazocin and medical compositions containing them |
| HU201318B (en) * | 1987-12-31 | 1990-10-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing dioxazoline derivatives and pharmaceutical compositions comprising same |
| DE69002217T2 (de) * | 1989-10-20 | 1993-10-21 | Akzo Nv | Dibenzodioxazecin- und Dibenzodioxaazacycloundecin-Derivate. |
| DE69622415T2 (de) * | 1995-09-19 | 2003-03-06 | Novo Nordisk A/S, Bagsvaerd | 12H-Dibenzo[d,g][1,3]dioxocin Derivate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705M (fr) * | 1963-04-18 | 1964-08-03 | Rhone Poulenc Sa | Nouvelles compositions anti-émétiques. |
| NL7202963A (de) * | 1972-03-07 | 1973-09-11 | ||
| NL176458C (nl) * | 1972-09-23 | 1985-04-16 | Akzo Nv | Werkwijze ter bereiding van een farmaceutisch preparaat en werkwijze voor de bereiding van daartoe geschikte actieve stoffen. |
| HU174126B (hu) * | 1977-08-02 | 1979-11-28 | Egyt Gyogyszervegyeszeti Gyar | Sposob poluchenija novykh proizvodnykh dibenzo-kvadratnaja skobka-d,g-kvadratnaja skobka zakryta-kvadratnaja skobka-1,3,6-kvadratnaja skobka zakryta-dioksazocina |
| DE3426720A1 (de) * | 1984-07-20 | 1986-01-23 | Hoechst Ag, 6230 Frankfurt | Benzthiazepinon- und benzthiazocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung |
-
1985
- 1985-12-20 HU HU854881A patent/HU195491B/hu not_active IP Right Cessation
-
1986
- 1986-12-10 AT AT0326986A patent/AT394366B/de not_active IP Right Cessation
- 1986-12-12 BE BE1/011589A patent/BE905907A/fr not_active IP Right Cessation
- 1986-12-17 CN CN198686108260A patent/CN86108260A/zh active Pending
- 1986-12-18 CH CH5108/86A patent/CH670638A5/de not_active IP Right Cessation
- 1986-12-18 PH PH34611A patent/PH24385A/en unknown
- 1986-12-18 SE SE8605457A patent/SE466399B/sv not_active IP Right Cessation
- 1986-12-19 CS CS869606A patent/CS262681B2/cs unknown
- 1986-12-19 DK DK616886A patent/DK616886A/da not_active Application Discontinuation
- 1986-12-19 YU YU218886A patent/YU45814B/sh unknown
- 1986-12-19 NO NO865179A patent/NO865179L/no unknown
- 1986-12-19 FR FR868617825A patent/FR2592043B1/fr not_active Expired - Lifetime
- 1986-12-19 AU AU66765/86A patent/AU589725B2/en not_active Ceased
- 1986-12-19 ES ES8603527A patent/ES2003994A6/es not_active Expired
- 1986-12-19 PL PL1986263134A patent/PL263134A1/xx unknown
- 1986-12-19 BG BG077613A patent/BG46004A3/xx unknown
- 1986-12-19 IT IT22780/86A patent/IT1199821B/it active
- 1986-12-19 PT PT83979A patent/PT83979B/pt not_active IP Right Cessation
- 1986-12-19 SU SU864028671A patent/SU1470187A3/ru active
- 1986-12-19 DD DD86298019A patent/DD256695A5/de not_active IP Right Cessation
- 1986-12-19 NL NL8603236A patent/NL8603236A/nl not_active Application Discontinuation
- 1986-12-19 CA CA000525829A patent/CA1291133C/en not_active Expired - Lifetime
- 1986-12-19 GB GB8630431A patent/GB2184445B/en not_active Expired
- 1986-12-19 FI FI865244A patent/FI83644C/fi not_active IP Right Cessation
- 1986-12-20 JP JP61302884A patent/JPS62158265A/ja active Pending
- 1986-12-22 DE DE19863643991 patent/DE3643991A1/de active Granted
-
1988
- 1988-05-18 US US07/195,691 patent/US4906622A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2172315C1 (ru) | Способ получения рацемических или оптически активных метил(2-галогенофенил)(6,7-дигидро-4н-тиено[3,2-с]пиридин-5-ил)ацетатов или их солей | |
| NO329710B1 (no) | Carvedilolfosfatsalter og/eller solvater derav, samt farmasoytiske preparater omfattende disse | |
| BR0313070B1 (pt) | Métodos para preparação de um diastereômero desejado de uma tetraidro-beta-carbolina e para preparação de um composto | |
| JPS60255764A (ja) | （ｒ）‐アルフア‐エチル‐２‐オキソ‐１‐ピリジンアセトアミド及びその製法並びに該化合物を含有する製薬組成物 | |
| USRE29588E (en) | Preparation of d-2-amino-1-butanol salts | |
| BRPI0607436B1 (pt) | Base cristalina do composto trans-1-((1r,3s)-6-cloro-3-fenil-indan1-il)-3,3-dimetil-piperazina, sua composição farmacêutica, seus usos, seu método de preparação, método para fabricação do referido composto, bem como base livre do referido composto | |
| US5663173A (en) | N-[(1,4-diazabicyclo[2.2.2] oct-2-yl)methyl] benzamide derivatives, their preparations and their application in therapeutics | |
| DE69519315T2 (de) | Aminoalkyl Benzoxazolinone und Benzothiazolinone, Verfahren zu deren Herstellung und sie enthaltende Zusammensetzungen | |
| PT99673B (pt) | Processo para a preparacao de derivados de 1-piperazino-indano e de composicoes farmaceuticas que os contem | |
| NO865179L (no) | Fremgangsmaate for fremstilling av optisk aktive 2-klor-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo(d,g)(1,3,6)dioxazociner. | |
| CA2437402A1 (en) | New crystal forms of oxcarbazepine and processes for their preparation | |
| JP2010509309A (ja) | ３−ベンジル−２−メチル−２，３，３ａ，４，５，６，７，７ａ−オクタヒドロベンゾ［ｄ］イソオキサゾール−４−オンの塩 | |
| WO2008080290A1 (fr) | Antagoniste selectif du recepteur m4 et utilisation medicale associee | |
| PT87160B (pt) | Processo para a preparacao de 3h-1,2,3-triazolo{4,5-d}pirimidinas | |
| PT86153B (pt) | Processo para a preparacao de inibidores de girase opticamente activos | |
| US5096900A (en) | (4-piperidyl)methyl-2,3-dihydro-1h-isoindole and -2,3,4,5-tetrahydro-1h-benzazepine derivatives, their preparation and their application in therapy | |
| FR2663929A1 (fr) | Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| NO124309B (de) | ||
| PT86424B (pt) | Processo para a preparacao de tetra-hidropirido-indoles substituidos | |
| US3903165A (en) | Ethynylaryl amines and processes for their preparation | |
| EP0573548B1 (de) | Neuro-schützende Mittel | |
| JP3033181B2 (ja) | ９―ジアシルアミノテトラヒドロアクリジン誘導体 | |
| JP2021531329A (ja) | ベンゾチオフェン化合物のマレイン酸塩、その結晶形式及びその用途 | |
| JP3000658B2 (ja) | ９―アミノカルボニルアミノテトラヒドロアクリジン誘導体 | |
| FI64353B (fi) | Foerfarande foer framstaellning av e-3-(4-bromfenyl)-n-metyl-3-(3-pyridyl)-allylamin till anvaendning som laekemedel |